Results 51 to 60 of about 169,886 (331)

Intrapancreatic accessory spleen false positive to 68Ga-Dotatoc: case report and literature review [PDF]

open access: yes, 2019
Background: Intrapancreatic accessory spleen (IPAS) is an uncommon finding of pancreatic mass. Differential diagnosis with pancreatic tumor, especially with non-functional neuroendocrine tumor (NF-NET), may be very hard and sometimes it entails ...
Bellato, V.   +9 more
core   +1 more source

Renal neuroendocrine tumors

open access: yesIndian Journal of Urology, 2009
Neuroendocrine tumors (NETs) are uncommon tumors that exhibit a wide range of neuroendocrine differentiation and biological behavior. Primary NETs of the kidney, including carcinoid tumor, small cell carcinoma (SCC), and large cell neuroendocrine carcinoma (LCNEC) are exceedingly rare.The clinicopathologic features of renal NETs diagnosed at a single ...
Brian R Lane, George Jour, Ming Zhou
openaire   +3 more sources

Gastroenteropancreatic Neuroendocrine Tumors [PDF]

open access: yesCA: A Cancer Journal for Clinicians, 2018
Abstract Neuroendocrine tumors (NETs) are heterogeneous malignancies arising from the diffuse neuroendocrine system. They frequently originate in the gastroenteropancreatic (GEP) tract and the bronchopulmonary tree, and their incidence has steadily increased in the last 3 decades.
Cives, Mauro, Strosberg, Jonathan R
openaire   +3 more sources

A nationwide, multi‐institutional collaborative retrospective study of colorectal neuroendocrine tumors in Japan

open access: yesAnnals of Gastroenterological Surgery, 2021
Aim Neuroendocrine tumors (NETs) are one of the subtypes of neuroendocrine neoplasms and are defined as epithelial neoplasms with predominant neuroendocrine differentiation.
Tatsuro Yamaguchi   +11 more
doaj   +1 more source

Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors [PDF]

open access: yes, 2015
Over the past few years, knowledge regarding the molecular pathology of sporadic pancreatic neuroendocrine tumors (PNETs) has increased substantially, and a number of targeted agents have been tested in clinical trials in this tumor type.
Ahn   +64 more
core   +1 more source

An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. [PDF]

open access: yes, 2013
BACKGROUND: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are heterogeneous with respect to biological behaviour and prognosis. As angiogenesis is a renowned pathogenic hallmark as well as a therapeutic target, we aimed to investigate the ...
A Couvelard   +47 more
core   +2 more sources

Plasma acylated and plasma unacylated ghrelin: useful new biomarkers in patients with neuroendocrine tumors?

open access: yesEndocrine Connections, 2016
To date, the value of fasting plasma acylated ghrelin (AG) and unacylated ghrelin (UAG) as potential novel biomarkers in patients with neuroendocrine tumors (NETs) is unknown.The aims of this study are to (i) compare fasting AG and UAG levels between ...
Roxanne C S van Adrichem   +6 more
doaj   +1 more source

Tumors in von Hippel–Lindau Syndrome: From Head to Toe—Comprehensive State-of-the-Art Review [PDF]

open access: yes, 2018
Von Hippel–Lindau syndrome (VHL) is an autosomal-dominant hereditary tumor disease that arises owing to germline mutations in the VHL gene, located on the short arm of chromosome 3.
Bhalla, Sanjeev   +6 more
core   +1 more source

Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?

open access: yesJournal for ImmunoTherapy of Cancer
Immune checkpoint inhibitors (ICIs) revolutionized the management of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers.
Davide Ciardiello   +10 more
doaj   +1 more source

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. [PDF]

open access: yes, 2020
PurposeImmune checkpoint blockade has improved outcomes across tumor types; little is known about the efficacy of these agents in rare tumors. We report the results of the (nonpancreatic) neuroendocrine neoplasm cohort of SWOG S1609 dual anti-CTLA-4 and ...
Baghdadi, Tareq Al   +21 more
core  

Home - About - Disclaimer - Privacy